Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Rosenkranz

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Mathematical Biosciences|July 2, 2003
Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivityYangxin Huang, Susan L Rosenkranz, Hulin Wu
HIV Clinical Trials|October 27, 2006
Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpointsRobin DiFrancesco, Susan L Rosenkranz, Jean Craft, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administrationJian-Feng Lu, Terrence F Blaschke, Charles Flexner, et al.
Metabolic Syndrome and Related Disorders|November 17, 2007
Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic AnalysisSusan L Rosenkranz, Kevin E Yarasheski, Michael F Para, et al.
Therapeutic Drug Monitoring|March 5, 2019
Sources of Variability and Accuracy of Performance Assessment in the Clinical Pharmacology Quality Assurance Proficiency Testing Program for AntiretroviralsRichard W Browne, Susan L Rosenkranz, Yan Wang, et al.
AIDS Research and Human Retroviruses|December 12, 2012
The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patientsLu Zheng, Susan L Rosenkranz, Babafemi Taiwo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 9, 2010
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177Yoninah S Cramer, Susan L Rosenkranz, Stephen D Hall, et al.
Drugs in R&D|September 7, 2017
Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309sJennifer J Kiser, Darlene Lu, Susan L Rosenkranz, et al.
Clinical Pharmacology and Therapeutics|May 7, 2003
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitorsCarla B Washington, Charles Flexner, Lewis B Sheiner, et al.
Biopharmaceutics & Drug Disposition|November 29, 2007
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteersQing Ma, Alan Forrest, Susan L Rosenkranz, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Mathematical Biosciences|July 2, 2003
Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivityYangxin Huang, Susan L Rosenkranz, Hulin Wu
HIV Clinical Trials|October 27, 2006
Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpointsRobin DiFrancesco, Susan L Rosenkranz, Jean Craft, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administrationJian-Feng Lu, Terrence F Blaschke, Charles Flexner, et al.
Metabolic Syndrome and Related Disorders|November 17, 2007
Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic AnalysisSusan L Rosenkranz, Kevin E Yarasheski, Michael F Para, et al.
Therapeutic Drug Monitoring|March 5, 2019
Sources of Variability and Accuracy of Performance Assessment in the Clinical Pharmacology Quality Assurance Proficiency Testing Program for AntiretroviralsRichard W Browne, Susan L Rosenkranz, Yan Wang, et al.
AIDS Research and Human Retroviruses|December 12, 2012
The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patientsLu Zheng, Susan L Rosenkranz, Babafemi Taiwo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 9, 2010
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177Yoninah S Cramer, Susan L Rosenkranz, Stephen D Hall, et al.
Drugs in R&D|September 7, 2017
Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309sJennifer J Kiser, Darlene Lu, Susan L Rosenkranz, et al.
Clinical Pharmacology and Therapeutics|May 7, 2003
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitorsCarla B Washington, Charles Flexner, Lewis B Sheiner, et al.
Biopharmaceutics & Drug Disposition|November 29, 2007
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteersQing Ma, Alan Forrest, Susan L Rosenkranz, et al.
Pageof 5